trans-4-([(2Z)-3-carboxyprop-2-enoyl]aminolmethyl)cyclohexanecarboxylic acid | 69907-68-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: trans-4-([(2Z)-3-carboxyprop-2-enoyl]aminolmethyl)cyclohexanecarboxylic acid
• 英文别名: N-(carboxyacryloyl)-4-(aminomethyl)-cyclohexane-1-carboxylic acid
• CAS: 69907-68-2
• 化学式: C₁₂H₁₇NO₅
• 分子量: 255.271
• InChiKey: XFEDBGCHJRFAAA-SMONXKMMSA-N

物化性质

• 熔点：
  192-194 °C
• 沸点：
  558.8±46.0 °C(Predicted)
• 密度：
  1.276±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.63
• 重原子数：
  18.0
• 可旋转键数：
  5.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  103.7
• 氢给体数：
  3.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  trans-4-([(2Z)-3-carboxyprop-2-enoyl]aminolmethyl)cyclohexanecarboxylic acid 在 N-羟基丁二酰亚胺 、 sodium acetate 、 乙酸酐 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 为溶剂， 反应 5.0h， 生成 N-(3-triethoxysilylpropyl)-4-(N'-maleimidylmethyl)cyclohexanecarboxamide
  参考文献：
  名称：

  N-(3-Triethoxysilylpropyl)-4-(N′-maleimidylmethyl)cyclohexanamide (TPMC): A heterobifunctional reagent for immobilization of oligonucleotides on glass surface

  摘要：

  A new heterobifunctional reagent, namely, N-(3-trieth oxysilylpropyl)-4-(N'-rnaleimidylmethyl)cyclohexanamide (TPMC) was developed and its potentiality for fixing of thiol (-SH) modified oligonucleo tides were tested. The covalent attachment of oligonucleotides with the reagent was achieved through its maleimide functionality at one end via stable thioether linkage while the other end bearing triethoxysily] functionality has been utilized for coupling with the virgin glass surface with simplified rnethodologies. Immobilization of oligonucleotides was achieved by two alternating ways. The PATH-1 involves formation of conjugate of reagent and SH-modified oligonucleotides through thioether linkage and was subsequently immobilized on unmodified glass surface through triethoxysilyl group and alternatively, PATH-2 involves reaction of reagent first with unmodified glass surface to get maleimide functionality on the surface and then the SH-modified oligonucleotides were immobilized via thioether linkage. The specificity of immobilization was tested by hybridization study with complementary fluorescein labeled oligonticleotide strand. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.014
• 作为产物：
  描述：

  马来酸酐 、 tranexamic acid 在 溶剂黄146 作用下， 生成 trans-4-([(2Z)-3-carboxyprop-2-enoyl]aminolmethyl)cyclohexanecarboxylic acid
  参考文献：
  名称：

  用N-三氟乙酰氧基琥珀酰亚胺方便地制备N-马来酰氨基酸琥珀酰亚胺酯

  摘要：

  摘要 使用 N-三氟乙酰氧基琥珀酰亚胺对容易获得的马来酰胺酸衍生物进行一锅环化和酯化，为获得各种有用的 N-马来酰氨基酸 N-羟基琥珀酰亚胺酯提供了一种方便且经济高效的途径。

  DOI：

  10.1080/00397910701750151

文献信息

• Linker, Antibody-Drug Conjugate Including Same and Use Thereof
  申请人：Academy of Military Medical Sciences

  公开号：US20210261505A1

  公开（公告）日：2021-08-26

  Provided are a linker represented by Formula I or I′, an antibody-drug conjugate containing the same, and use of thereof, a pharmaceutical composition comprising the antibody-drug conjugate, and use of the antibody-drug conjugate for treating and/or preventing a disease.

  提供的是由公式I或I′表示的连接剂，含有相同抗体-药物偶联物及其用途，包含该抗体-药物偶联物的药物组合物以及使用该抗体-药物偶联物治疗和/或预防疾病的用途。
• [EN] ANTICANCER CONJUGATE<br/>[FR] CONJUGUÉ ANTICANCÉREUX
  申请人：ADAMED SP ZOO

  公开号：WO2014141094A1

  公开（公告）日：2014-09-18

  An anticancer conjugate, which comprises a fusion protein comprising domain (a), which is the functional fragment of a sequence of soluble human TRAIL (hTRAIL) protein beginning with an amino acid at a position not lower than hTRAIL95 or a sequence having at least 70% identity with said functional fragment, domain (b) which is the sequence of an effector peptide having proapoptotic, antiangiogenic, antiproliferative or pore forming activity, and conjugation domain (d) for attachment of a chemical compound selected from the group consisting of the sequences Cys Ala Ala Ala Cys Ala Ala Cys and Cys Ala Ala Cys Ala Ala Ala Cys, and a molecule of a chemical compound Z having antiblastic activity, which is attached to said conjugation domain (d) of said fusion protein directly or via a conjugation linker L.

  一种抗癌结合物，包括融合蛋白，该融合蛋白包括以下部分：（a）功能性片段，该片段是以不低于hTRAIL95位置的氨基酸开始的可溶性人类TRAIL（hTRAIL）蛋白序列的片段，或者具有与该功能性片段至少70%同源性的序列；（b）是具有促凋亡、抗血管生成、抗增殖或形成孔活性的效应肽序列；以及（d）用于连接来自以下序列的化学化合物的结合结构域，该序列包括Cys Ala Ala Ala Cys Ala Ala Cys和Cys Ala Ala Cys Ala Ala Ala Cys，以及具有抗肿瘤活性的化学化合物Z的分子，该分子附着在所述融合蛋白的结合结构域（d）上，直接或通过结合连接物L连接。
• LINKER, ANTIBODY-DRUG CONJUGATE INCLUDING SAME, AND USE THEREOF
  申请人：Academy of Military Medical Sciences

  公开号：EP3838893A1

  公开（公告）日：2021-06-23

  Provided are a linker represented by Formula I or I', an antibody-drug conjugate containing the same, and use of thereof, a pharmaceutical composition comprising the antibody-drug conjugate, and use of the antibody-drug conjugate for treating and/or preventing a disease.

  本文提供了一种由式 I 或式 I'表示的连接体、一种含有该连接体的抗体-药物共轭物及其用途、一种含有该抗体-药物共轭物的药物组合物，以及该抗体-药物共轭物在治疗和/或预防疾病方面的用途。
• [EN] LINKER, ANTIBODY-DRUG CONJUGATE INCLUDING SAME, AND USE THEREOF<br/>[FR] LIEUR, CONJUGUÉ ANTICORPS-MÉDICAMENT LE COMPRENANT ET UTILISATION ASSOCIÉE<br/>[ZH] 连接子、含连接子的抗体偶联药物及连接子的用途
  申请人：ACAD OF MILITARY MEDICAL SCIENCES

  公开号：WO2020035027A1

  公开（公告）日：2020-02-20

  提供了一种式I或式I'所示的连接子、含连接子的抗体偶联药物、连接子的用途、包含抗体偶联药物的药物组合物以及所述抗体偶联药物用于治疗和/或预防疾病的用途。
• In Situ Formation of <i>N</i>-Trifluoroacetoxy Succinimide (TFA-NHS): One-Pot Formation of Succinimidyl Esters, <i>N</i>-Trifluoroacetyl Amino Acid Succinimidyl Esters, and <i>N</i>-Maleoyl Amino Acid Succinimidyl Esters
  作者：Nicholas M. Leonard、Jarmila Brunckova

  DOI：10.1021/jo201686e

  日期：2011.11.4

  A method for the in situ formation of N-trifluoroacetoxy succinimide (TFA-NHS) and its application in the formation of succinimidyl esters is presented. The developed method provides N-trifluoroacetyl and N-maleoyl amino acid succinimidyl esters from a variety of amino acids using a one-pot, high-yielding protocol. Investigations into the formation of an N-maleoyl amino acid succinimidyl ester supported the proposal of a revised reaction mechanism, and contributed to the optimization of the reaction conditions.